Abstract

Objective. To collect data about the usage of EVRA – the transdermal contraceptive patch in clinical practice among Estonian women. Data about efficacy (incl cycle control), tolerability, compliance as well as satisfaction among the users were evaluated. Also, satisfaction and compliance  with previously used contraceptive method was recorded.
Methods. The study enrolled 442 women aged 17-45 yrs in five study centres in Estonia. Each EVRA patch was applied for 7 days during 3 consecutive weeks (21 days) followed by 1  patch-free week. Six contraceptive cycles were recorded.
Results. High compliance (90%) was observed with EVRA. The compliance rates did not differ significantly between age groups, still the best compliance rates were observed among the youngest (<21 yrs) users. Side effects were similar to oral hormonal contraceptives, in addition local application site reactions were reported. One pregnancy was reported during the study. Satisfaction among users was high and improved throughout the study. Cycle control was good.
The risk for spotting or breakthrough bleeding  decreased during prolonged use. The following EVRA parameters were considered particularly important: ease of use, 1-weekly administration, transdermal application and good tolerability. This is of clinical relevance since 76% of oral contraceptive users forget the pill (only 24% have perfect compliance).
Conclusion. EVRA is a valuable contraceptive method providing high compliance rates, contraceptive efficacy, cycle control, ease of use and satisfaction among users, and thereby is an important addition to the selection of contraceptive methods also in Estonia.